Matches in Wikidata for { <http://www.wikidata.org/entity/Q92638078> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q92638078 description "2019 թվականի հունիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q92638078 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92638078 description "im Juni 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92638078 description "scientific article published on 11 June 2019" @default.
- Q92638078 description "wetenschappelijk artikel" @default.
- Q92638078 description "наукова стаття, опублікована 11 червня 2019" @default.
- Q92638078 name "First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment" @default.
- Q92638078 name "First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment" @default.
- Q92638078 type Item @default.
- Q92638078 label "First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment" @default.
- Q92638078 label "First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment" @default.
- Q92638078 prefLabel "First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment" @default.
- Q92638078 prefLabel "First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment" @default.
- Q92638078 P1433 Q92638078-F4A34A52-3C36-489F-94D7-1A8039472C0B @default.
- Q92638078 P1476 Q92638078-6F982DF3-BFAE-4C2B-BF85-80590767C0ED @default.
- Q92638078 P2093 Q92638078-1BFBF172-89ED-4C27-ADB9-5994F6635B86 @default.
- Q92638078 P2093 Q92638078-2DF128DA-4AB7-4291-9D17-D4E8A29219A7 @default.
- Q92638078 P2093 Q92638078-3B5BD5CF-4F74-4B0E-9D2A-4ACE4EB84906 @default.
- Q92638078 P2093 Q92638078-78344F25-D832-47CB-A534-342F2F5EED12 @default.
- Q92638078 P2093 Q92638078-D22D57AE-EE02-411C-82BA-FE3DDAB7A924 @default.
- Q92638078 P31 Q92638078-F4D0557F-588C-450E-909F-EC7EFF2AFCD4 @default.
- Q92638078 P356 Q92638078-47E0B244-703F-4DB6-9B5D-D80F53A84916 @default.
- Q92638078 P577 Q92638078-8F6C2FC4-0A7C-46C1-80A9-D8758B42202E @default.
- Q92638078 P698 Q92638078-7C50BC04-EC7E-41F4-8BD4-E6ED01EAB319 @default.
- Q92638078 P921 Q92638078-EEFAE861-43D2-41CF-A64B-1B614B4F87CD @default.
- Q92638078 P356 IMT-2019-0061 @default.
- Q92638078 P698 31181973 @default.
- Q92638078 P1433 Q18713038 @default.
- Q92638078 P1476 "First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment" @default.
- Q92638078 P2093 "M Catherine Pietanza" @default.
- Q92638078 P2093 "Sheenu Chandwani" @default.
- Q92638078 P2093 "Thomas Burke" @default.
- Q92638078 P2093 "Vamsidhar Velcheti" @default.
- Q92638078 P2093 "Xin Chen" @default.
- Q92638078 P31 Q13442814 @default.
- Q92638078 P356 "10.2217/IMT-2019-0061" @default.
- Q92638078 P577 "2019-06-11T00:00:00Z" @default.
- Q92638078 P698 "31181973" @default.
- Q92638078 P921 Q13896859 @default.